Becton, Dickinson and Company (BDX)
Automate Your Wheel Strategy on BDX
With Tiblio's Option Bot, you can configure your own wheel strategy including BDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BDX
- Rev/Share 74.2577
- Book/Share 88.4488
- PB 2.1161
- Debt/Equity 0.7593
- CurrentRatio 1.1026
- ROIC 0.0467
- MktCap 53648063373.0
- FreeCF/Share 8.8543
- PFCF 21.0385
- PE 33.5644
- Debt/Assets 0.3523
- DivYield 0.0222
- ROE 0.0631
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BDX | RBC Capital Mkts | -- | Sector Perform | -- | $211 | Sept. 25, 2025 |
| Downgrade | BDX | Citigroup | Buy | Neutral | -- | $185 | May 22, 2025 |
| Downgrade | BDX | Raymond James | Outperform | Market Perform | -- | -- | May 2, 2025 |
| Downgrade | BDX | Goldman | Buy | Neutral | -- | $192 | May 2, 2025 |
| Downgrade | BDX | Piper Sandler | Overweight | Neutral | -- | $185 | May 2, 2025 |
| Downgrade | BDX | William Blair | Outperform | Market Perform | -- | -- | May 1, 2025 |
| Downgrade | BDX | BofA Securities | Buy | Neutral | -- | $190 | May 1, 2025 |
| Downgrade | BDX | Wells Fargo | Overweight | Equal Weight | -- | -- | May 1, 2025 |
| Upgrade | BDX | Citigroup | Neutral | Buy | $255 | $275 | Oct. 1, 2024 |
News
BD & Henry Ford Health Tie-Up to Enhance Community Pharmacy Experience
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX partners with Henry Ford Health to deploy BD Rowa Vmax robots, aiming to streamline 24/7 pharmacy access in Michigan.
Read More
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Published: September 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Fluorescence Cell Market Forecasts USD 6.37 Billion by 2034 at 7.29% CAGR
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fluorescence Cell Market (2024 - 2034) Report by Towards Healthcare, a sister firm of Precedence Research Fluorescence Cell Market (2024 - 2034) Report by Towards Healthcare, a sister firm of Precedence Research
Read More
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Should Value Investors Buy Becton, Dickinson and Company (BDX) Stock?
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
FRANKLIN LAKES, N.J. , Sept. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the placement of the 1,000th BD Rhapsody™ System, a flagship instrument for single-cell multiomics analysis, at Addenbrooke's Hospital of the University of Cambridge, United Kingdom.
Read More
BDX vs. MMSI: Which Stock Should Value Investors Buy Now?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Ex-Dividend Reminder: Alphabet, Becton, Dickinson And Rogers
Published: September 04, 2025 by: Forbes
Sentiment: Neutral
On 9/8/25, Alphabet, Becton, Dickinson, and Rogers Communications will all trade ex-dividend for their respective upcoming dividends. Alphabet will pay its quarterly dividend of $0.21 on 9/15/25, Becton, Dickinson will pay its quarterly dividend of $1.04 on 9/30/25, and Rogers Communications will pay its quarterly dividend of $0.50 on 10/3/25.
Read More
Best Dividend Aristocrats For September 2025
Published: August 27, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY in August.
Read More
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Becton, Dickinson: Great Time To Buy This Dividend Aristocrat
Published: August 18, 2025 by: Seeking Alpha
Sentiment: Positive
BDX is now attractively valued with a forward PE of 13.7, well below its historical average, making it a compelling value stock. Strong growth in Pharmaceutical Systems and Interventional segments, margin expansion, and a robust innovation pipeline drive business momentum. The upcoming Waters Corp. spin-out will focus BDX on high-growth, recurring revenue segments, enhancing long-term earnings potential.
Read More
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Heartland's 3 Tactical Q2 Moves: Trimming Risk, Harvesting Losses, And Raising Cash
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Neutral
We remain patient and opportunistic, raising cash to capitalize on future volatility and focusing on stocks meeting our 10 Principles of Value Investing™. We initiated a position in Applied Materials, leveraging semiconductor industry weakness, and see secular tailwinds and potential for multiple expansion to the low $300s. Sensient Technologies delivered strong results on natural color demand, but with valuation now higher, the risk-reward is less compelling than at initial purchase.
Read More
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
Read More
Becton Dickinson Q3 Beats Estimates On Medical Device Boom
Published: August 07, 2025 by: Benzinga
Sentiment: Positive
As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company BDX are reporting robust financial performances that highlight their resilience and strategic adaptability. The company's stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.
Read More
Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q3 Earnings
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Becton, Dickinson and Company (BDX) Q3 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Becton, Dickinson and Company (NYSE:BDX ) Q3 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Christopher J. DelOrefice - Executive VP & CFO Greg Rodetis - Senior VP, Treasurer & Head of Investor Relations Thomas E.
Read More
Can Sustained Product Demand Drive BDX Stock Before Q3 Earnings?
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
Read More
Curious about Becton Dickinson (BDX) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J. , July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics and other convenient points of care.
Read More
Best Dividend Kings: July 2025
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
Read More
BD Partners With Waters to Build High-Volume Diagnostics Leader
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
Read More
Becton Dickinson gets its spinoff deal, but the stock is still falling
Published: July 14, 2025 by: Market Watch
Sentiment: Neutral
Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.
Read More
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brands Anticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five Delivers …
Read More
Becton, Dickinson: A Dividend King Facing Challenges Offers Value
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Positive
Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.
Read More
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
Read More
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
FRANKLIN LAKES, N.J. , May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology 1 and Cancer Medicine 2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients.
Read More
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Read More
About Becton, Dickinson and Company (BDX)
- IPO Date 1973-02-21
- Website https://www.bd.com
- Industry Medical - Instruments & Supplies
- CEO Thomas E. Polen Jr.
- Employees 70000